Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00270998 · ClinicalTrials.gov registry record · Phase 3

ATLAS: Ambulatory Treatments for Leakage Associated With Stress

A Phase 3 study, sponsored by NICHD Pelvic Floor Disorders Network.

Completed
Registry status
Phase 3
Development phase
445
Enrollment target

NCT00270998: Completed Phase 3 study, sponsored by NICHD Pelvic Floor Disorders Network.

NCT00270998 is a Phase 3 study that has completed, run by NICHD Pelvic Floor Disorders Network. The registered enrollment target is 445 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00270998, a Phase 3 study, has completed, sponsored by NICHD Pelvic Floor Disorders Network.

COMPLETED
Registry status
Phase 3
Development phase
445 participants
Enrollment target

Study Summary

Stress urinary incontinence is the uncontrollable leakage of urine with physical effort or stress, such as coughing, sneezing, or exercise. Treatment for stress incontinence can be surgical or non-surgical. Different non-surgical treatments include pelvic muscle exercises and pessary use. Pelvic muscle exercises (often known as "Kegel" exercises) train and strengthen the pelvic muscles and improve incontinence. A pessary is a medical device that fits inside the vagina to give the urethra and bladder extra support and prevent or reduce urinary incontinence. Exercises and pessary use can help women with stress incontinence but it is not known which treatment is better, or if a combination of the two treatments at the same time is best. This study will determine whether pelvic muscle training and exercises, pessary use, or a combination of both exercises and pessary is most effective at improving incontinence in women. The study's primary hypothesis is that pessary use is more effective than pelvic muscle exercises after 3 months of treatment.

Primary Outcome

PGI-I, Patient Global Impression of Improvement, is a five-point scale that ranges from "not at all" to "very much better." Participants were considered a success if they responded "much better" or "very much better," or a failure if they responded otherwise.

Interventions

  • BEHAVIORAL Behavioral Therapy
  • DEVICE Intravaginal Pessary
  • DEVICE Pessary combined with behavioral therapy

Trial Details

FieldValue
Enrollment Target 445 participants
Start Date 2005-06
Est. Completion 2008-12
Phase Phase 3

What the finished NCT00270998 record still lists

NCT00270998 is an interventional study that assigns participants to a tested intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).

The record links to 0 conditions, and to 3 interventions - of which Behavioral Therapy is the first listed.

NCT00270998 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00270998 about?

NCT00270998 is a clinical study titled "ATLAS: Ambulatory Treatments for Leakage Associated With Stress". Stress urinary incontinence is the uncontrollable leakage of urine with physical effort or stress, such as coughing, sneezing, or exercise. Treatment for stress incontinence can be surgical or non-surgical. Different non-surgical treatments include pelvic muscle exercises and pessary use. Pelvic mus...

What is the current status of trial NCT00270998?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 445 participants. The study started on 2005-06. Estimated completion is 2008-12.

What interventions are being tested in trial NCT00270998?

The interventions under investigation include: Behavioral Therapy (BEHAVIORAL), Intravaginal Pessary (DEVICE), Pessary combined with behavioral therapy (DEVICE).

Who is sponsoring clinical trial NCT00270998?

This trial is sponsored by NICHD Pelvic Floor Disorders Network, which has 17 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00270998's enrollment target sits among peer trials

445 864th of 2000 higher than 1,137 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01280994 · 445 participants · Phase 2

    Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

  • NCT03504800 · 445 participants

    OCT in Diagnosis of Irregular Corneas

  • NCT04751435 · 445 participants · NA

    Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

  • NCT06348394 · 444 participants · NA

    Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00270998, the US trial registry maintained by the National Library of Medicine. NCT00270998 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.